Moderna Beats Q1 Revenue Guidance Despite Heavy Litigation Losses

Moderna (MRNA) outperformed its first-quarter revenue expectations, posting $400 million for the period. This represents a $300 million increase over the previous year, largely attributed to the execution of long-term strategic partnerships, most notably with the United Kingdom government for its spring booster campaign. Approximately 80% of the quarter's revenue was generated in international markets. Despite the top-line growth, the company's bottom line was heavily impacted by legal obligations. Moderna reported a GAAP net loss of $1.3 billion, or $3.40 per share, compared to a $1.0 billion loss in the prior year. Management clarified that this widening loss was primarily driven by a settlement with Arbutus and Genevant. Excluding the litigation settlement, the company's financial health showed improvement, with the non-GAAP net loss falling to $0.5 billion, a decrease of over 50% year-over-year. The cost of sales for the quarter reached $955 million, of which $878 million was related to the settlement. A further lump-sum payment of $950 million is scheduled for the third quarter of 2026. Looking forward, Moderna provided second-quarter revenue guidance between $50 million and $100 million. The company is also aggressively implementing cost-reduction measures; research and development expenses fell 24% to $649 million, while SG&A expenses declined 18% to $173 million. While Moderna intends to appeal certain legal liabilities, it continues to advance its pipeline with new European Union approvals for its respiratory portfolio.